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Abstract
Background: Obesity and related diseases of the metabolic syndrome contribute to the major health problems in
industrialized countries. Alterations in the metabolism of lipid classes and lipid species may significantly be involved in these
metabolic overload diseases. However, little is known about specific lipid species in this syndrome and existing data are
contradictive.
Methods: In this study, we quantified plasma lipid species by electrospray ionization tandem mass spectrometry (ESI-MS/
MS) in obese subjects before and after 3 month weight loss as well as in a control group.
Results: The comparison of obese subjects with control subjects before weight loss revealed significantly lower
lysophosphatidylcholine (LPC) concentrations in obesity. LPC concentrations did not significantly increase during the
observed period in the weight loss group. Analysis of LPC species revealed a decrease of most species in obesity and
negative correlations with C-reactive protein (CRP) and body mass index (BMI). Correlating BMI ratio before and after weight
loss with the ratio of total LPC and individual LPC species revealed significant negative relationships of LPC ratios with BMI
ratio.
Conclusions: Our findings contribute to the contradictive discussion of the role of LPC in obesity and related chronic
inflammation strongly supporting pre-existing data in the literature that show a decrease of LPC species in plasma of obese
and a potentially anti-inflammatory role in these subjects.
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Introduction
Obesity has become one of the major worldwide health
problems. Obesity is associated with a variety of severe diseases
and co-morbidities including type 2 diabetes, atherosclerosis, and
hypertension. These health problems are well-known to be related
to alterations in plasma lipids like increased fasting triglycerides,
high low density lipoprotein (LDL) cholesterol, low high density
lipoprotein (HDL) cholesterol and elevated blood glucose and
insulin levels [1]. However, only very few and in part, contra-
dictive data exist on alterations of the plasma lipidome in obesity
and subsequent weight loss.
Mass spectrometry-based lipid analysis today allows profiling of
a large variety of lipid classes and species in a single sample. This
technology has been successfully applied in studies of metabolic
disorders. In particular, in type 2 diabetes (T2D) specific plasma
phospholipids have been associated with insulin sensitivity [2], the
inclusion of plasma lipid species significantly improved the
classification of individuals at risk for T2D [3]. T2D and
prediabetes were positively associated with plasma ceramide
(Cer), dihydroceramide, phosphatidylethanolamine (PE), phospha-
tidylglycerol and phosphatidylinositol (PI) while a negative
relationship has been shown with ether-linked phosphatidylcho-
lines (PC) [4]. Moreover, in coronary artery disease, several lipid
species including alkylphospholipid and PI species were identified
as discriminatory for stable and unstable coronary artery disease
[5]. In hypertensive patients a deficiency in plasma ether lipids,
specifically in ether PC and ether PE, has been demonstrated [6].
Since obesity is strongly related to these diseases it seems
obvious that relevant alterations of the plasma lipidome may be
observed in these subjects. A marked increase in plasma levels of
saturated di- and triacyglycerols as well as increased levels of PC,
PE, PE ether and lysophosphatidylcholine (LPC) have been
reported in obesity [6]. In a monozygotic twin study obesity was
primarily related to increases in LPC and to decreases in ether
phospholipids [7]. In contrast, Barber et al. [8] found in a small
cohort a reduction in a number of LPC species in obese and obese
individuals with T2D.
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In a study of diet-induced weight loss in obese, a reduction of
PC and, predominantly short chain fatty acid triacylglycerols in
serum was observed, while other lipid classes as sphingolipids and
LPC remained unaffected by weight loss [9].
Interestingly, alterations of plasma LPC are found in most studies
concerned with obesity. Plasma LPC mainly originates from
lecithin-cholesterol acyltransferase (LCAT) activity [10], hepatic
secretion [11] or from PC by action of phospholipase A2 [12].
To further elucidate these contradictive data on plasma lipid
classes and species in obesity and their potential role in the
development of metabolic abnormalities, we here investigated
obese subjects before and three months of diet-induced weight loss
and compared them to lean controls. Using an ESI-MS/MS based
lipidomic approach, we performed quantitative lipidomic profiling
as well as routine clinical chemistry of individual plasma samples
before and after weight loss.
Methods
Study population
The study population of the ongoing ‘‘Obesity and Weight
Reduction Remodeling Study’’ has been described previously
[13,14]. Control and obese subjects for the study population
published here have been recruited from 03/2005 to 04/2008 at
the University Hospital of Regensburg.
Obese patients intending to participate in a weight reduction
programme were offered enrolment in this study, prior to the start
of the programme. Patients were eligible for enrolment, if they
were 18–59 years old, presented with a body mass index (BMI).
30 kg/m2 and a constant body weight in the last 3 months, and if
they signed a declaration of consent. Patients were excluded, if
they had one or more of the following:.10% reduction of body
weight in the last 6 months, cancer, pregnancy, therapy with
steroids or thyroid hormones, known heart disease, known type 1
or type 2 diabetes, known inflammatory bowel, rheumatoid, or
systemic diseases, known chronic renal failure, known liver
diseases, mental disorders, or addiction to drugs or alcohol.
For comparison, healthy normal weight control subjects (BMI
20–25 kg/m2) of comparable age and gender distribution were
also studied. They were recruited by flyers, advertisements, and
friend referrals. The study was approved by the local Ethics
Committee (Universita¨tsklinikum Regensburg, Ethikkommission
der medizinischen Fakulta¨t, proposal 05/001). All subjects had
given their written informed consent to participate in the study.
The baseline characteristics of the study population are
summarized in Table 1.
Weight reduction program
Weight reduction in obese subjects was pursued by Optifast-52
(Nestle´ HealthCare Nutrition GmbH) comprising a 52-week
medical weight loss program encompassing diet, lifestyle changes,
counseling and exercises. For the present study, only data of the
initial three month of the ‘‘Active Weight Loss Phase’’ were
utilized. During this phase, patients consume 800 kilocalories per
day consisting only of meal replacements supplied by Optifast
(shakes, nutritional bars, soups) and water.
Phenotyping and plasma sampling
Blood samples were drawn after a 12-h overnight fasting
between 7:00 and 9:00 a.m. before starting (t = 0) and after three
months of the weight reduction program (t = 1). At the same time,
height and weight were recorded. Serum samples for lipid analysis
were analyzed the same day, for lipid species analysis, EDTA-
pasma samples were stored at 280uC before measurement.
Clinical chemistry and lipid analysis
Cholesterol, HDL-cholesterol, LDL-cholesterol and triglycer-
ides were determined on ADVIA 1800 System (Siemens), using
commercial kits.
Table 1. Baseline characteristics in obese and control subjects before and after weight loss.
Controls obese
Before weight loss After weight loss Before weight loss After weight loss
N (all) 23 57
N(male) 9 25
N (female) 14 32
Age (years) 38.22613.77 46.40613.14*
BMI (kg/m2) 22.5562.13 22.5162.17 41.6268.18*** 35.0067.74###;NNN
Waist (cm) 78.9567.72 77.2665.90 124.32617.90*** 110.27617.67###. NNN
Hip (cm) 99.9564.56 98.6764.29 133.21615.88*** 121.73614.87###. NNN
Waist/Hip 0.7960.06 0.7860.05 0.9460.09 0.9160.09###. NN
Chloesterol (mg/dl) 187.57625.18 196.23630.76 192.46 639.80 169.04632.38##. NNN
LDL cholesterol (mg/dl) 105.056 25.18 113.39628.98 117.04638.07 99.82631.42NNN
HDL cholesterol (mg/dl) 64.7669.79 64.83611.77 48.93612.09*** 45.88610.03###. N
Triglyceride (mg/dl) 68.86624.95 90.26638.79 140.09677.02*** 100.98640.64NNN
*p,0.05 obese vs. control before weight loss.
*** p,0.001 obese vs. control before weight loss.
##p,0.01 obese vs. control after weight loss.
###p,0.001 obese vs. control after weight loss.
Np,0.05 obese before vs. after weight loss.
NNp,0.01 obese before vs. after weight loss.
NNNp,0.001 obese before vs. after weight loss.
doi:10.1371/journal.pone.0111348.t001
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Lipids were quantified by direct flow injection electrospray
ionization tandem mass spectrometry (ESI-MS/MS) in positive
ion mode, using the analytical setup and strategy described
previously [15,16]. A precursor ion of m/z 184 was used for PC,
sphingomyelin (SM) [15] and LPC [17]. Neutral loss fragments
were used for the following lipid classes: PE and PI with a loss of
141 and 277 Da, respectively [18,19]. PE-based plasmalogens
(PE-P) were analyzed according to the principles described by
Zemski-Berry [20]. Sphingosine-based Cer and hexosylceramides
(HexCer) were analyzed, using a fragment ion of m/z 264 [21].
Free cholesterol (FC) and cholesteryl ester (CE) were quantified,
using a fragment ion of m/z 369, after selective derivatization of FC
[16]. Quantification was acchieved using two non-naturally
occurring internal standards (IS) for each lipid class (except for
PI, SM was calculated, using PC IS and PE-based plasmalogens
were calculated, using PE IS) and calibration lines generated by
standard addition of a number of naturally occurring species to
plasma. Deisotoping and data analysis for all lipid classes was
performed by self programmed Excel Macros as described
previously [15,22]. Lipid species were annotated, according to
the recently published proposal for shorthand notation of lipid
structures that are derived from mass spectrometry [23].
Glycerophospholipid species annotation was based on the
assumption of even numbered carbon chains only. SM species
annotation is based on the assumption that a sphingoid base with
two hydroxyl groups is present.
Statistical analysis
All data are expressed as mean 6 SD. Statistical analysis was
performed using IBM SPSS statistics 19 software. Statistical
significance was determined by the Mann-Whitney-U-test for
comparing controls vs. obese and the Wilcoxon-paired-samples-
test for comparing subjects before and after weight loss. Linear
relationships were determined by the Pearson correlation coeffi-
cient. A p,0.05 was considered as statistically significant.
Results
Plasma lipid profile in obesity and weight loss
The lipid species of each class were examined by measuring
individual samples. As expected, CE was the most abundant lipid in
control samples (39916576 mM).Othermajor lipid classes were PC
(18066303 mM), SM (441664 mM), and LPC (287666 mM). All
other analyzed lipid classes were detected at levels lower than
50 mM.
The comparison of obese subjects with control subjects before
weight loss (t = 0) revealed significantly lower LPC concentrations
in obesity (control vs. obese: 287666 mM vs. 243654 mM,
p= 0.005). In addition FC (11766175 mM vs. 13096266 mM,
p= 0.039), PI (15.664.0 mM vs. 18.964.9 mM, p=0.032),
dihydrosphingomyelin (8.062.6 mM vs. 12.163.9 mM, p,
0.001) were elevated. After 3 month of weight loss (t = 1)
hexosylceramide (0.860.1 mM vs. 1.060.3 mM, p= 0.007) and
dihydrosphingomyelin (7.862.4 mM vs. 10.964.0 mM, p,0.001)
were elevated in obese subjects compared to controls. Lower
LPC concentrations in obesity could still be observed
(311673 mM vs. 226659 mM, p,0.001) at t = 1. In obese lower
levels of total cholesterol (40236539 mM vs. 35876652 mM,
p= 0.005), PC (19516316 mM vs. 16266333 mM, p,0.001),
plasmalogens (50.3613.8 mM vs. 36.1613.0 mM, p,0.001), PI
(17.764.3 mM vs. 15.263.4 mM, p= 0.032), and Cer
(7.061.2 mM vs. 6.261.2 mM, p= 0.027) were observed after
weight loss. (Figure 1).
The observed effects were independent of sex. In particular, the
observed differences between lean and obese subjects in plasmaLPC
remained significant in a gender specific evaluation. LPC was lower
in plasma of males (307660 mM vs. 249666 mM, p=0.037) and
Figure 1. Plasma levels of lipid classes in obese and control subjects. Lipid concentrations in EDTA-plasma were measured by ESI-MS/MS in
obese and control subjects at entry in the study (t = 0) and after 3 month of weight loss of obese subjects (t = 1). Data are expressed as mean 6 SD.
*p,0.05 obese vs. control, **p,0.01 obese vs. control *** p,0.001 obese vs. control.
doi:10.1371/journal.pone.0111348.g001
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females (275669 mM vs. 238644 mM, p= 0.048) before weight
loss, and lower levels were also observed in males (351678 mM vs.
241 mM667 mM, p,0.001) and females (286658 mM vs.
214650 mM, p,0.001) after 3 month weight loss.
Plasma LPC species in obesity and weight loss
To elucidate whether the decrease in plasma LPC in obesity is
due to alterations in certain LPC species, the concentration of
distinct LPC species was analyzed in all samples included in the
study. LPC 16:0 was the most abundant species in control subjects
(146637 mM) followed by LPC 18:0 (56.5614.9 mM), LPC 18:2
(34.5612.5 mM) and LPC 18:1 (28.4612.5 mM). All other LPC
species were detected at concentrations below 10 mM. At t = 0 in
obese subjects significantly lower plasma concentrations were
found in almost all LPC species analyzed, namely LPC15:0, LPC
18:3, LPC 18:2, LPC 18:1, LPC 20:5, LPC 20:4, LPC 20:0, LPC
22:6, and LPC 22:5. After 3 month weight loss (t = 1), besides for
LPC 20:4 the observed differences in plasma levels persisted.
Moreover, in addition to the LPC species mentioned above LPC
16:1, LPC16:0, LPC 18:0 and LPC 20:3 were found decreased in
obese subjects at t = 1. (Figure 2).
Correlation of LPC species with BMI and CRP
Since decreased plasma levels of total LPC and LPC species
may be due to obesity and the inflammatory status in these
subjects, respectively, we correlated BMI and CRP as an indicator
of inflammation with total LPC as well as with different LPC
species within the group of obese subjects. We found significant
negative correlations of BMI with LPC 15:0, LPC 18:1, LPC 18:2,
LPC 18:3, LPC20:0, and LPC 22:6. Summing up groups of LPC
species, we found significant negative correlations of BMI with all
unsaturated, monounsaturated as well as with polyunsaturated
LPC. Similar to BMI, CRP correlated negatively with LPC 15:0,
LPC18:0, LPC 18:1, LPC18:2, LPC 20:0, LPC 20:4, LPC 22:5,
LPC 22:6. All analyzed subgroups of LPC species also correlated
significantly with CRP. (Table 2).
Correlation of LPC species with BMI during weight loss
We addressed the question if weight loss might be able to
normalize LPC plasma concentrations. Therefore, we analyzed
the correlation of the ratio of BMI before and after weight loss
with the ratio of LPC and LPC species. We found a significant
negative correlation of the total LPC ratio with BMI. Among LPC
species significant correlations were detected for LPC 16:0, LPC
18:1, LPC 20:0, LPC 20:4, LPC 22:5, and LPC 22:6. Summing up
groups of LPC species, we found significant negative correlations
of BMI ratio with the ratio of unsaturated, monounsaturated and
saturated LPC species (Table 3).
Discussion
Obesity and related diseases in the context of the metabolic
syndrome significantly contribute to major worldwide health
problems. Since circulating plasma lipids very likely play an
important role in this syndrome complex, we performed quanti-
tative plasma lipid profiling in obesity and weight loss supple-
menting pre-existing data.
Lipidomic analysis revealed PC, SM, and LPC as most
abundant lipid classes in plasma of obese as well as control
subjects. Similar results from 21 healthy fasting blood donors have
been published by our group previously [24] and are in good
accordance with comparative data from others [6].
In comparison to lean controls in our study, plasma LPC levels
were found significantly decreased in obese subjects before and still
after weight loss. This was due to lower plasma levels of nearly all
LPC species, in particular the main species LPC 16:0, 18:0, 18:1
Figure 2. Plasma lysophosphatidylcholine levels in obese and control subjects. Lysophosphatidycholine (LPC) species in EDTA-plasma
were measured by ESI-MS/MS in obese and control subjects at entry in the study (t = 0) and after 3 month of weight loss of obese subjects (t = 1).
Data are expressed as mean 6 SD. *p,0.05 obese vs. control, **p,0.01 obese vs. control *** p,0.001 obese vs. control.
doi:10.1371/journal.pone.0111348.g002
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Table 2. Correlation between CRP and BMI with LPC species.
LPC species CRP BMI
R value P value R value P value
LPC 15:0 20.273 0.016 20.359 0.001
LPC 16:1 20.029 0.803 20.051 0.658
LPC 16:0 20.183 0.111 20.032 0.780
LPC 18:3 20.182 0.114 20.251 0.028
LPC 18:2 20.434 ,0.001 20.490 ,0.001
LPC 18:1 20.419 ,0.001 20.389 ,0.001
LPC 18:0 20.305 0.007 20.054 0.643
LPC 19:0 20.039 0.733 20.007 0.951
LPC 20:5 20.150 0.193 20.192 0.095
LPC 20:4 20.288 0.011 20.120 0.300
LPC 20:3 20.044 0.705 20.027 0.818
LPC 20:0 20.403 ,0.001 20.403 ,0.001
LPC 22:6 20.357 ,0.001 20.305 0.007
LPC 22:4 20.327 0.004 20.081 0.483
LPC 22:0 20.005 0.967 20.067 0.562
Sum LPC 20.328 0.004 20.190 0.098
Sum LPC saturated 20.229 0.045 20.045 0.697
Sum LPC unsaturated 20.431 ,0.001 20.433 ,0.001
Sum LPC monounsaturated 20.395 ,0.001 20.370 0.001
Sum LPC polyunsaturated 20.426 ,0.001 20.442 ,0.001
doi:10.1371/journal.pone.0111348.t002
Table 3. Correlation between the Ratio t = 1/t = 0 of LPC species with the Ratio t = 1/t = 0 of BMI in obese subjects.
LPC species BMI
R value P value
LPC 15:0 20.008 0.954
LPC 16:1 0.002 0.990
LPC 16:0 20.401 0.002
LPC 18:3 0.015 0.913
LPC 18:2 20.183 0.174
LPC 18:1 20.293 0.027
LPC 18:0 20.022 0.873
LPC 19:0 0.255 0.055
LPC 20:5 0.034 0.804
LPC 20:4 20.465 ,0.001
LPC 20:3 0.044 0.744
LPC 20:0 20.313 0.018
LPC 22:6 20.303 0.022
LPC 22:4 20.246 0.065
LPC 22:0 20.148 0.271
Sum LPC 20.310 0.019
Sum LPC saturated 20.314 0.017
Sum LPC unsaturated 20.261 0.050
Sum LPC monounsaturated 20.270 0.043
Sum LPC polyunsaturated 20.250 0.061
doi:10.1371/journal.pone.0111348.t003
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and 18:2. Similar decreases of most LPC species were found in a
mouse model of 6 weeks on a high fat diet [8]. Moreover, in small
cohorts (n = 9–11) of lean, obese, and obese individuals with T2D,
lower plasma levels of total LPC, LPC 15:0, 18:0, 18:1, 18:2 and
20:4 were detected previously [8]. The same tendency was
observed for most other LPC species analyzed and could be
confirmed by our data from a larger study group. Interestingly, no
difference in the LPC profile of obese and obese subjects with type
2 diabetes could be found in that study [8]. In contrast, a study in
monozygotic twins revealed in acquired obesity a relationship of
obesity with increased LPC levels while ether phospholipids were
found decreased [7]. Among the LPC species LPC 16:0, 18:0,
18:1, 18:2, and 20:4 were mainly altered in obesity. This study also
demonstrated a negative correlation of LPC with insulin sensitivity
[7]. In trend, an increase of LPC species towards higher BMI
levels was also observed by Graessler et al. comparing the plasma
lipidome of men with BMI.27.5 kg/m2 relative to a control
group of men with BMI ,27.5 kg/m2. However, significant
differences were only detected for LPC 16:0 [6].
The discrepant data describing alterations in LPC plasma levels
related to BMI and obesity remain not fully understood. One
important factor may be the exclusion of genetic factors in the twin
study by Pietilainen et al. [7] which selectively analyzes the effects
of acquired obesity in their study. Genetic factors in obesity,
alterations in lipid metabolism and development of the metabolic
syndrome are well known (reviewed in [25]) and may contribute
significantly to the results of our study and the study of Barber
et al. [8]. A recently published study detected a direct correlation
of LPC with the number of servings of full-fat dairy foods in
overweight and obese subjects with metabolic syndrome [2]. This
supports the concept that mainly genetic factors contributing to
obesity may be causal for decreased LPC plasma levels rather than
nutritive and environmental factors that seem to increase LPC
with higher BMI.
In a study published 2008 Schwab et al. [9] could not observe
significant alterations in LPC plasma levels after a 33 week period
of weight loss in obese subjects. However, we found a significant
negative relationship of the total LPC ratio as well as of several
LPC ratios with change of BMI ratio during weight loss. This
indicates that effective and long-lasting weight loss may indeed be
able to normalize altered LPC levels. Studies published so far,
were potentially still too short to detect a full revision of profound
and long-time lasting alterations in metabolism even after
significant weight loss. In addition, decreases in LPC levels may
be partially also due to genetic factors contributing to the
development of severe overweight.
In our study, total LPC as well as a number of LPC species not
only correlate negatively with BMI but also with CRP, possibly
indicating a role of LPC as a marker of inflammation in obesity.
The association of obesity with elevated levels of CRP, as a marker
of inflammation and predictor of cardiovascular risk is well-know
(reviewed in [26]) and were also found by others e.g. by Pietilainen
et al. [7]. However, the role of LPC in the context of obesity and
inflammation still remains poorly understood. A large variety of
mainly pro-, but also antiatherogenic effects of LPC as well as a
role in acute and chronic inflammation have been described so far
[27]. In particular, in chronic inflammatory diseases local and
systemic increases are described as characteristic features [28].
Moreover, in cardiovascular disease, certain phospholipases A2
generating LPC from cell membrane or lipoprotein derived PC
[27] have been evaluated as biomarkers of cardiovascular risk.
This includes the family of secretory phospholipases A2 (sPLA2) of
which elevated levels and certain polymorphisms of GIIA sPLA2
predict cardiovascular events. Similar results were described for
lipoprotein phospholipase A2 (LpPLA2), indicating higher risk for
coronary heart disease and ischemic stroke in individuals with
higher LpPLA2 activity or concentration [29].
In contrast, also decreased LPC levels in inflammation and anti-
inflammatory effects of LPC have been reported. In sepsis patients
absolute concentrations of total LPC as well as of major LPC
species were found significantly decreased compared to healthy
controls. In these patients the LPC-PC ratio was higher in
survivors, compared with non-survivors of sepsis. Low LPC-PC
ratios at day 4 and 11, in patients fulfilling all sepsis criteria, were
significantly associated with 30 days mortality [30]. These findings
were also confirmed in a mouse model of experimental sepsis, in
which administration of LPC protected against lethality accom-
panied by decreased TNFa and IL-1b levels [31]. Interestingly, in
cancer patients LPC also correlated negatively with CRP. In this
study-population, a decrease of LPC was also associated with
cancer-related weight loss [32]. Furthermore, in a recently
published study we could demonstrate a beneficial role of the
major LPC species LPC 16:0, 18:0 and 18:2 which were negatively
associated with total mortality and partially with coronary artery
disease [33]. In addition to cardiovascular diseases, a depletion of
plasma LPC 18:2 has recently also been observed in patients with
Alzheimers Disease and mild cognitive impairment [34].
Regarding these data, decreased LPC levels in our study
population of obese subjects may not only be caused by
overweight, but may contribute also to chronic inflammation.
LPC effects on inflammatory processes may be mediated, at least
in part by LPC binding G protein coupled receptor (GPR) G2A,
which appears to play a functional role in the modulation of
activation, migration and apoptosis of a variety of immune cells
including neutrophils, macrophages and lymphocytes [27,28].
Our data support a protective and anti-inflammatory and
striking role of LPC that is lost in the chronic inflammatory status
in obesity. Since obesity is often a life-long process, the study
period might have been too short a duration to detect the possible
beneficial effect of weight loss.
However, further investigations will be needed to elucidate the
pleiotropic role of LPC and other bioactive lipids.
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